Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Gynecology

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 21 articles: HTML format

Single Articles

April 2025
1. DURAKI D, Jabeen M, Mao C, Wang L, et al
   A Necrosis Inducer Promotes an Immunogenic Response and Destroys Ovarian Cancers in Mouse Xenografts and Patient Ascites Organoids.
   Cancer Lett. 2025 Apr 29:217738. doi: 10.1016/j.canlet.2025.217738.
   PubMed     Abstract available
   
   
   March 2025
2. LI H, Chatla S, Liu X, Tian Z, et al
   ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
   Cancer Lett. 2025;613:217505.
   PubMed     Abstract available
   
   
   February 2025
3. WANG Q, Liu W, Fan Y, Liu S, et al
   Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.
   Cancer Lett. 2025 Feb 25:217588. doi: 10.1016/j.canlet.2025.217588.
   PubMed    
   
   
   
4. TAMURA T, Nagai S, Masuda K, Imaeda K, et al
   mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer.
   Cancer Lett. 2025 Feb 17:217565. doi: 10.1016/j.canlet.2025.217565.
   PubMed     Abstract available
   
   
   
5. GUO M, He M, Dang Y, Lei L, et al
   Predictors of para-aortic lymph node metastasis based on pathological diagnosis via surgical staging in patients with locally advanced cervical cancer: A multicenter study.
   Cancer Lett. 2025 Feb 15:217545. doi: 10.1016/j.canlet.2025.217545.
   PubMed     Abstract available
   
   
   
6. LI X, Yang X, Lin S, Cong H, et al
   Perineural Invasion in Cervical Cancer.
   Cancer Lett. 2025 Feb 14:217561. doi: 10.1016/j.canlet.2025.217561.
   PubMed     Abstract available
   
   
   December 2024
7. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
   N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
   Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
   PubMed     Abstract available
   
   
   November 2024
8. FIELD NR, Dickson KA, Nassif NT, Marsh DJ, et al
   SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
   Cancer Lett. 2024;605:217282.
   PubMed     Abstract available
   
   
   
9. BHOWMIK AD, Shaw P, Gopinatha Pillai MS, Rao G, et al
   Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.
   Cancer Lett. 2024 Nov 28:217357. doi: 10.1016/j.canlet.2024.217357.
   PubMed     Abstract available
   
   
   October 2024
10. NING Y, Chen Y, Tian T, Gao X, et al
    S100A7 Orchestrates Neutrophil Chemotaxis and Drives Neutrophil Extracellular Traps (NETs) Formation to Facilitate Lymph Node Metastasis in Cervical Cancer Patients.
    Cancer Lett. 2024 Oct 7:217288. doi: 10.1016/j.canlet.2024.217288.
    PubMed     Abstract available
    
    
    September 2024
11. LEWIS F, Beirne J, Henderson B, Norris L, et al
    Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
    Cancer Lett. 2024 Sep 26:217279. doi: 10.1016/j.canlet.2024.217279.
    PubMed     Abstract available
    
    
    August 2024
12. WU H, Sun C, Cao W, Teng Q, et al
    Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Cancer Lett. 2024;602:217192.
    PubMed     Abstract available
    
    
    July 2024
13. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
    The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
    Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
    PubMed     Abstract available
    
    
    
14. XU J, Lu W, Wei X, Zhang B, et al
    Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Cancer Lett. 2024;593:216928.
    PubMed     Abstract available
    
    
    June 2024
15. FENG X, Ji Z, Fan X, Kong Y, et al
    ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
    Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
    PubMed     Abstract available
    
    
    
16. MENG H, Miao H, Zhang Y, Chen T, et al
    YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
    Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
    PubMed     Abstract available
    
    
    
17. YU Y, Lyu C, Li X, Yang L, et al
    Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Cancer Lett. 2024;596:217022.
    PubMed     Abstract available
    
    
    April 2024
18. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    PubMed     Abstract available
    
    
    
19. KAUR P, Shankar E, Gupta S
    EZH2-mediated development of therapeutic resistance in cancer.
    Cancer Lett. 2024;586:216706.
    PubMed     Abstract available
    
    
    March 2024
20. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
    Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
    Cancer Lett. 2024;585:216673.
    PubMed     Abstract available
    
    
    
21. CAO C, Xu Q, Zhu Z, Xu M, et al
    Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer.
    Cancer Lett. 2024 Mar 10:216809. doi: 10.1016/j.canlet.2024.216809.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.